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ABSTRACT
Purpose: Component-resolved diagnostics (CRD) is expected to provide additional 
diagnostic information in allergic patients. PROTIA™ Allergy-Q 64 Atopy®, a recently 
developed CRD-based multiplex specific immunoglobulin E (sIgE) assay, can quantitatively 
measure sIgE to major allergen components.
Methods: The sIgE detection by PROTIA™ Allergy-Q 64 Atopy® and ImmunoCAP® assays was 
compared using the sera of 125 Korean allergic patients. Group 1 and 2 allergens of house dust 
mites (HDMs; Dermatophagoides farinae (Der f ) 1 and Der f 2 in PROTIA™ Allergy-Q 64 Atopy®, 
Dermatophagoides pteronyssinus (Der p) 1 and Der p 2 in ImmunoCAP®), Bet v 1, Fel d 1, Que a 1, 
ω-5 gliadin, α-lactalbumin, β-lactoglobulin, casein and α-Gal were measured by both assays.
Results: Comparing the results from the 2 assays, the agreement rate for all the 10 allergens 
was > 88% (group 1 HDM allergen, 100%; group 2 HDM allergen, 94.6%; Bet v 1, 97.4%; Fel 
d 1, 90.5%; Que a 1, 89.2%; α-lactalbumin, 96%; β-lactoglobulin, 88%; casein, 88%; ω-5 
gliadin, 96%; α-Gal, 100%). Correlation analysis indicated that, all the 10 allergen sIgEs 
showed more than moderate positive correlation (Pearson correlation coefficients > 0.640). 
Additionally, intra-class comparison showed more than high correlation for all the 10 
allergens (Spearman's rank correlation coefficients > 0.743).
Conclusions: PROTIA™ Allergy-Q 64 Atopy® is reliable and comparable to the ImmunoCAP® 
assay for component-resolved diagnosis.
Keywords: Immunoassay; immunoglobulin E; allergens
INTRODUCTION
Proving the presence of allergen-specific immunoglobulin E (sIgE) is essential for 
identification of culprit allergens.1 Traditionally, skin prick test (SPT) has been used as 
a reliable method to identify the presence of sIgE.2 However, SPT is not a quantitative 
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test and is difficult to compare results among patients. Serologic sIgE measurement has 
advantages over SPT in these aspects, and it has been considered an effective alternative to 
SPT as well as radio-allergosorbent test, another recommended method for sIgE detecton.3,4 
However, serologic sIgE measurement has certain disadvantages. The tests are usually 
based on total allergen extracts for the detection of sIgE, making it difficult to distinguish 
true sensitization from cross-reactivity of other allergens.5 For example, cross-reactive 
carbohydrate determinants that are antigen structures shared by allergenic components 
from taxonomically distant allergens give false positive results.6 Total allergen extracts also 
contain clinically irrelevant allergens such as easily denatured food allergens. To standardize 
total extracts is also a challenge, and inadequate standardization can cause insufficient 
concentration of clinically relevant major allergens in total extracts.7 These disadvantages can 
lead not only to false positives but also to false negative results. Therefore, labor-intensive 
oral food challenge (OFC) tests are required for accurate diagnosis of food allergies.8 
However, food challenge test can result in side reactions such as anaphylaxis. Additionally, 
placebo-control is difficult during food challenge tests.
Recently, with biomolecular technological advances, identification of sIgEs to the major 
clinically relevant allergen components has become possible.9,10 Component-resolved 
diagnostics (CRD) is a better approach to the treatment of allergic patients as it facilitates the 
discrimination of clinically significant sIgE from irrelevant sIgE. CRD is also very helpful in 
selecting appropriate allergens when performing immunotherapy to polysensitize patients.11 
Furthermore, it can help predict the prognosis of allergic patients.5
ImmunoCAP® (Thermo Fisher Scientific, Uppsala, Sweden), a gold standard method for 
quantitative sIgE measurement, is widely used to detect sIgE for allergenic components.12 
However, because ImmunoCAP® is a singleplex assay, it is difficult to detect multiple 
allergens simultaneously and the cost per allergen is higher than that when using the 
multiplex assay. To solve this problem, the PROTIA™ Allergy-Q 64 Atopy® (Proteometech, 
Seoul, Korea) was developed by upgrading the PROTIA™ Allergy-Q, which is a multiplex sIgE 
measurement assay for total crude allergens.13 The PROTIA™ Allergy-Q 64 Atopy® is based 
on the enzyme immunoassay technique that uses nitrocellulose membrane as the solid-phase 
for allergen immobilization. It can detect sIgEs for 10 major allergen components (group 
1 house dust mite [HDM], group 2 HDM allergens, Bet v 1, Fel d 1, Que a 1, α-lactalbumin, 
β-lactoglobulin, casein, ω-5 gliadin and α-Gal) in addition to 49 total crude allergen extracts.
This study aimed to validate the CRD concept of PROTIA™ Allergy-Q 64 Atopy® in 
comparison with ImmunoCAP®. This was the first study to validate the sIgE measurement 
ability of PROTIA™ Allergy-Q 64 Atopy®.
MATERIALS AND METHODS
Study participants
One hundred twenty-five Korean allergic patients who visited the Allergy and Asthma Center 
of Severance Hospital for the diagnosis and treatment of their allergic diseases were enrolled 
in this study. The enrolled patients were clinically diagnosed with allergic rhinitis or food 
allergy and did not have other chronic diseases such as autoimmune disease, cancer and 
chronic infections, or other immune-related disease. Blood samples were collected from 
all patients to perform diagnostic tests using the PROTIA™ Allergy-Q 64 Atopy® and the 
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ImmunoCAP®. Severance Hospital Ethical Review Board approved this study (No. 4-2017-1258)  
and informed consent was waived.
Serum preparation and allergen selection
Five milliliters of whole blood was collected in a vacuum tube (Vacuette®; Greiner Bio-One  
GmbH, Kremsmünster, Austria) for serum separation. Serum was separated by 
centrifugation at 3,000 rpm for 5 minutes, then supernatant was aliquoted into several round 
bottom tubes (5-mL BD Falcon™ tubes; BD Bioscience Discovery Labware, Bedford, MA, 
USA), and stored at −76°C until use.
For detection of sIgE, Dermatophagoides farinae (Der f ) 1 and Der f 2 were measured using the 
PROTIA™ Allergy-Q 64 atopy®, while Dermatophagoides pteronyssinus (Der p) 1 and Der p 2 
were measured using the ImmunoCAP®.Other allergen components (Bet v 1, Fel d 1, Que a 1, 
α-lactalbumin, β-lactoglobulin, casein, ω-5 gliadin and α-Gal) were measured by both assays.
In vitro allergen sIgE measurements
Both PROTIA™ Allergy-Q 64 Atopy® and the ImmunoCAP® were operated according to 
the manufacturers' instructions. The sIgEs for allergenic components that were adequate 
for clinical diagnosis were measured in each serum. Demographic data according to the 
allergenic components is shown in Table 1. The results of ImmunoCAP® were not provided to 
the person measuring sIgE using the PROTIA™ Allergy-Q 64 Atopy®. The sIgE detection limit 
of PROTIA™ Allergy-Q 64 Atopy® was 0.15 kUA/L, and that of ImmunoCAP® was 0.10 kUA/L. 
However, the sIgE classification of the 2 assays was identical (class 0, negative: below 0.35 
kUA/L; class 1, 0.35–0.7 kUA/L; class 2, 0.7–3.5 kUA/L; class 3, 3.5–17.5 kUA/L; class 4, 17.5–50 
kUA/L; class 5, 50–100 kUA/L; and class 6, above 100 kUA/L). The sIgE values ≥ 0.35 kUA/L 
were regarded as positive.
Statistical analysis
Positive sIgE detection by the 2 assays was compared by χ2 test, and the degree of correlation 
was expressed as Cohen's kappa value (κ). Cohen's kappa values were categorized as 
almost perfect (0.8–1.0), substantial (0.6–0.8), moderate (0.4–0.6), fair (0.2–0.4) or poor 
correlations (below 0.2).14 Pearson correlation coefficient was used to make quantitative 
comparison, and the degree of correlation was expressed as a Pearson correlation coefficient 
value (r). Correlation coefficient values were categorized as very high positive (0.9–1.0), 
high positive (0.7–0.9), moderate positive (0.5–0.7), low positive (0.3–0.5), or negligible 
correlations (0.0–0.3).15 To evaluate the class consistency between the 2 assays (intra-class 
comparison), measured sIgE values were classified as mentioned above. Classes of each 
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Table 1. Demographic characteristics of the study subjects according to allergen
Allergen No. of subjects (%) Clinical diagnosis Men:women Mean age ± SD
Group 1 mite 56 (44.8) Allergic rhinitis 21:35 39.0 ± 14.3
Group 2 mite 56 (44.8) Allergic rhinitis 21:35 39.0 ± 14.3
Bet v 1 39 (31.2) Allergic rhinitis 15:24 38.6 ± 14.6
Fel d 1 42 (33.6) Allergic rhinitis 16:26 39.0 ± 14.5
Que a 1 37 (29.6) Allergic rhinitis 14:23 39.0 ± 15.0
α-lactalbumin 25 (20.0) Milk allergy 19:6 4.6 ± 4.3
β-lactoglobulin 25 (20.0) Milk allergy 19:6 4.6 ± 4.3
Casein 25 (20.0) Milk allergy 19:6 4.6 ± 4.3
ω-5 gliadin 25 (20.0) Wheat allergy, WDEIA 15:10 27.6 ± 19.6
α-Gal 6 (4.8) Red meat allergy 2:4 55.0 ± 18.0
Total 125 (100.0) 64:61 31.7 ± 21.1
SD, standard deviation; WDEIA, wheat dependent exercise induced anaphylaxis.
sIgE were compared by Spearman's rank correlation coefficient, and degree of correlation 
was expressed as Spearman's rho value (ρ). Spearman's rho values were categorized as very 
high positive correlation (0.9–1.0), high positive (0.7–0.9), moderate positive (0.5–0.7), low 
positive (0.3–0.5) or negligible (below 0.3).15 SPSS 23.0 (SPSS Inc., Chicago, IL, USA) was 
used to analyze the results.
RESULTS
Qualitative comparison between the 2 assays
Comparing the positive results obtained using the PROTIA™ Allergy-Q 64 Atopy® and the 
ImmunoCAP®, at least 88% agreement rates (for β-lactoglobulin and casein) were seen 
between the 2 assays (Table 2). Group 1 HDM, α-Gal showed 100% agreement. In Cohen's 
kappa analysis, group 1 HDM allergens (κ = 1), group 2 HDM allergens (κ = 0.890), Bet v 1  
(κ = 0.949), α-lactalbumin (κ = 0.915), ω-5 gliadin (κ = 0.865) and α-Gal (κ = 1) showed 
almost perfect correlation between the 2 assay results. Fel d 1 (κ = 0.795), Que a 1 (κ = 0.682), 
casein (κ = 0.694) and β-lactoglobulin (κ = 0.719) showed substantial correlation.
Quantitative comparison between the 2 assays
Quantitative comparison between the results obtained from the 2 assays showed significant 
correlation (Table 3). All 10 allergens showed more than moderate positive correlation  
(r > 0.640). Very high correlations were observed in cases of α-lactalbumin (r = 0.962), ω-5 
gliadin (r = 0.926) and α-Gal (r = 0.926). High positive correlations were seen with group 
1 HDM allergens (r = 0.899), group 2 HDM allergens (r = 0.817), Bet v 1 (r = 0.855), Que a 1 
(r = 0.870) and casein (r = 0.808). Moderate positive correlation was observed with Fel d 1 
(r=0.686) and β-lactoglobulin (r = 0.640).
Intra-class comparison between the 2 assays
While examining the class consistency in intra-class comparison, the 2 assays showed more 
than high intra-class correlation for all the 10 allergens (Table 4, Figure). Very high positive 
intra-class correlations were observed with group 1 HDM allergens (ρ = 0.976), group 2 HDM 
major allergens (ρ = 0.932), Bet v 1 (ρ = 0.953), α-lactalbumin (ρ = 0.926), ω-5 gliadin (ρ = 0.904) 
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Table 2. Qualitative comparison of ImmunoCAP® and PROTIA™ Allergy-Q 64 Atopy®
Allergen ImmunoCAP® PROTIA™ Allergy-Q 64 Atopy® Agreement rate κ value
Positive Negative Positive Negative
Group 1 mite 28 28 28 28 100.0† 1†
Group 2 mite 32 24 33 23 94.6† 0.890†
Bet v 1 19 20 18 21 97.4† 0.949†
Fel d 1 17 25 13 29 90.5† 0.795†
Que a 1 9 28 7 30 89.2† 0.682†
α-lactalbumin 16 9 15 10 96.0† 0.915†
β-lactoglobulin 16 9 19 6 88.0† 0.719†
Casein 20 5 17 8 88.0† 0.694†
ω-5 gliadin 20 5 21 4 96.0† 0.865†
α-Gal 3 3 3 3 100.0* 1*
Values are presented as number (%). For detection of sIgE to group 1, 2 mite allergens, Der p 1 and Der p 2 were measured by ImmunoCAP®, Der f 1 and Der f 2 
by PROTIA™ Allergy-Q 64 atopy. The κ = Cohen's kappa coefficient, Cohen's kappa values were categorized as almost perfect (0.8–1.0), substantial (0.6–0.8), 
moderate (0.4–0.6), fair (0.2–0.4) or poor correlations (below 0.2).
Der p, Dermatophagoides pteronyssinus; Der f, Dermatophagoides farina; sIgE, specific immunoglobulin E.
*P < 0.05, †P < 0.001.
and α-Gal (ρ = 0.935). High intra-class correlations were seen with Fel d 1 (ρ = 0.897), Que a 1 
(ρ = 0.743), β-lactoglobulin (ρ = 0.821) and casein (ρ = 0.879).
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Table 3. Quantitative comparison of ImmunoCAP® and PROTIA™ Allergy-Q 64 Atopy®
Allergen Correlation coefficient value Degree of correlation P value
Group 1 mite 0.899 High < 0.001
Group 2 mite 0.817 High < 0.001
Bet v 1 0.855 High < 0.001
Fel d 1 0.686 Moderate < 0.001
Que a 1 0.870 High < 0.001
α-lactalbumin 0.963 Very high < 0.001
β-lactoglobulin 0.640 Moderate 0.001
Casein 0.808 high < 0.001
ω-5 gliadin 0.931 Very high < 0.001
α-Gal 0.926 Very high 0.008
Pearson correlation coefficient was used to compare detection of sIgE between the PROTIA™ Allergy-Q 64 Atopy® 
with the ImmunoCAP®. The r = Pearson correlation coefficient value. Pearson correlation coefficient values were 
categorized as very high positive (0.9–1.0), high positive (0.7–0.9), moderate positive (0.5–0.7), low positive 
(0.3–0.5) or negligiblecorrelations (0.0–0.3).
Table 4. Intra-class comparison of ImmunoCAP® and PROTIA™ Allergy-Q 64 Atopy®
Allergen Spearman's rho value Degree of correlation P value
Group 1 mite 0.976 Very high < 0.001
Group 2 mite 0.932 Very high < 0.001
Bet v 1 0.953 Very high < 0.001
Fel d 1 0.897 High < 0.001
Que a 1 0.743 High < 0.001
α-lactalbumin 0.926 Very high < 0.001
β-lactoglobulin 0.821 High < 0.001
Casein 0.879 High < 0.001
ω-5 gliadin 0.904 Very high < 0.001
α-Gal 0.935 Very high 0.006
Spearman's correlation coefficient was used to evaluate the class consistency between the PROTIA™ Allergy-Q 
64 Atopy® and the ImmunoCAP®. Spearman's rho values were categorized as very high positive (0.9–1.0), high 
positive (0.7–0.9), moderate positive (0.5–0.7), positive (0.3–0.5) or negligible correlations (below 0.3).
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Figure. Intra-class comparison of ImmunoCAP® with PROTIATM Allergy-Q 64 Atopy®. Measured sIgEs were classified as class 0: below 0.35 kUA/L, class 1: 0.35-0.7 
kUA/L, class 2: 0.7-3.5 kUA/L, class 3: 3.5-17.5 kUA/L, class 4: 17.5-50 kUA/L, class 5: 50-100 kUA/L and class 6: above 100 kUA/L. Statistical values for intra-class 
comparison are shown in Table 4. Der p, Dermatophagoides pteronyssinus; Der f, Dermatophagoides farina. (continued to the next page)
DISCUSSION
PROTIA™ Allergy-Q 64 Atopy® is a newly developed first CRD-based multiplex sIgE detection 
assay in Korea. The current study aimed to validate the IgE detection ability of the PROTIA™ 
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Figure. (Continued) Intra-class comparison of ImmunoCAP® with PROTIATM Allergy-Q 64 Atopy®. Measured sIgEs were classified as class 0: below 0.35 kUA/L, 
class 1: 0.35-0.7 kUA/L, class 2: 0.7-3.5 kUA/L, class 3: 3.5-17.5 kUA/L, class 4: 17.5-50 kUA/L, class 5: 50-100 kUA/L and class 6: above 100 kUA/L. Statistical 
values for intra-class comparison are shown in Table 4. Der p, Dermatophagoides pteronyssinus; Der f, Dermatophagoides farina.
Allergy-Q 64 Atopy® for 10 important inhalant and food allergen components in comparison 
with the commonly used singleplex ImmunoCAP® assay. Our observations indicated that the 
PROTIA™ Allergy-Q 64 Atopy® is effective in detection of sIgE to 10 allergen components 
(Der f 1, Der f 2, Bet v 1, Fel d 1, Que a 1, α-lactalbumin, β-lactoglobulin, casein, ω-5 gliadin 
and α-Gal).
Ten allergen components thought to be most important were selected to be measured in 
PROTIA™ Allergy-Q 64 Atopy®. HDMs are the one of the most common causes of respiratory 
allergy.16 Among them, Der f was reported as the dominant species in Korea.17,18 Therefore, 
Der f 1 and Der f 2 were selected in PROTIA™ Allergy-Q 64 Atopy®. Birch and oak are 
the most common cause of pollinosis in Korea.19,20 Because Bet v 1 is the major allergen 
of birch pollen, and Que a 1 is the major allergen of oak pollen, these are important for 
diagnosing seasonal respiratory allergy. In addition to this, Bet v 1 and Que a 1 belong to 
the pathogenesis-related protein class 10 (PR-10) family. The PR-10 family is common cause 
of oral allergy syndrome.21 Due to the instability of the causative allergen of oral allergy 
syndrome, it can be destroyed during the production of commercial food extracts. Thus, SPT 
using these extracts may show false negative results.22 Therefore, sIgEs for Bet v1 and Que 
a 1 can help clinicians diagnose oral allergy syndrome.23 Unlike the allergen components 
of dog, Fel d 1, the major allergen of cat, is known to be a useful allergen component for 
diagnosis.24 In addition, considering that pet allergy has been increasing worldwide, Fel d 
1 is one of the important allergen components.25 The α-gal syndrome, allergy to red meat, 
is generally characterized by urticaria, angioedema, anaphylaxis, and gastrointestinal 
symptoms occurring 3–6 hours after ingesting red meat including beef, pork or lamb.26 SPT 
and sIgE for crude meat extracts such as beef, pork or lamb are known to be not valuable for 
the differential diagnosis of α-gal syndrome.27 Contrarily, sIgE for α-gal is known to have 
diagnostic value in α -gal syndrome.28 PROTIA™ Allergy-Q 64 Atopy® detects IgE for α-gal 
using bovine thyroglobulin (bTG). In a recent study, the specificity of IgE for α-gal (bTG) to 
diagnose red meat allergy was 92.3%.29 Cow's milk allergy is one of the most common food 
allergies in children.30,31 There are 2 main proteins in cow's milk that can cause food allergy. 
Casein fraction accounts for 80% of milk protein and whey fraction accounts for 20%. 
Casein fraction (Bos d 8) consists of αS1-casein, αS2-casein, β-casein and κ-casein. PROTIA™ 
Allergy-Q 64 Atopy® can detect sIgE for Bos d 8. Whey fraction consists of α-lactalbumin, 
β-lactoglobulin, immunoglobulins, bovine serum albumin and traces of lactoferrin.31 Of 
these, α-lactalbumin and β-lactoglobulin are the most important allergens of the whey 
fraction. CRD-based diagnosis of milk allergy showed similar positive predictive value 
(PPV) and better negative predictive value (NPV) compared with total crude allergen-based 
diagnosis.32 Furthermore, according to the casein sIgE level, persistent milk allergy or milk 
tolerance, and allergic reaction to baked milk might be predicted.33-35 Nevertheless, casein 
sIgE level cannot replace OFC test completely.34,36 However, it might reduce unnecessary OFC 
in many cases.
In this study, all allergens showed good agreement rates for detection by both the assays. 
However, slight differences were observed in agreement rates according to the allergenic 
components. This may be due to some differences in the 3-dimensional (3D) structure of 
the allergens used to detect IgE in the PROTIA™ Allergy-Q 64 Atopy® and ImmunoCAP®.37 
Many recombinant proteins having a sequence identical to its natural form have structures 
that differ from the native ones,38 and sIgE reactivity is influenced by the differences in the 3D 
structure of the molecule.39
428https://e-aair.org https://doi.org/10.4168/aair.2019.11.3.422
Multiplex sIgE CRD Assay for Allergy Diagnosis
In recent years, the diagnostic approach to detect allergic disease using CRD is being applied 
in clinical practice. Although ImmunoCAP® can detect sIgE to allergenic components, it 
provides only singleplex sIgE measurements. However, ImmunoCAP ISAC®, the currently 
available CRD-based multiplex sIgE measurement,40 can detect 112 molecular allergen 
components from 51 allergen sources. Although it has the advantage of high number of sIgE 
measurements, it requires considerable expertise in interpretation of the results obtained. 
In contrast, PROTIA™ Allergy-Q 64 Atopy® can detect 10 important major inhalant and food 
allergen components. Therefore, it is relatively easy to interpret the result and more feasible 
compared with ImmunoCAP ISAC®. Moreover, while the ImmunoCAP ISAC® measures 
sIgE only semi-quantitatively, the PROTIA™ Allergy-Q 64 Atopy® allows quantitative 
measurements of sIgE.
In Korea, multiplex sIgE measurement system is popular instead of singleplex, likely due 
to the reimbursement policy of the Korean Health Insurance Program, which only permits 
6 singleplex sIgE measurements. Only in exceptional cases, for examples, children under 6 
years old, 12 measurements have been permitted. Therefore, the multiplex sIgE system that 
can detect dozens of traditional sIgEs has been prescribed approximately 5 times more than 
the ImmunoCAP® for the last 5 years (2013–2017).41 Considering this real situation in Korea, 
PROTIA™ Allergy-Q 64 Atopy®, could be a useful CRD assay for Korean allergic patients.
The current study has some limitations. First, the HDM allergenic components were different 
between the 2 assays (PROTIA™ Allergy-Q 64 Atopy®, Der f 1 and Der f 2; ImmunoCAP®, Der 
p 1 and Der p 2). This is because ImmunoCAP® cannot detect allergen components of (Der f 1 
and Der f 2). However, Der f 1 and Der p 1 share 81% of sequence identity, and Der f 2 and Der 
p 2 share 87% sequence identity,42,43 Therefore, there is considerable cross reactivity within 
the group. Because of this, the comparison between Der f 1 with Der p 1 or Der f 2 with Der 
p 2 has clinical implications. Second, both assays have different detection limits (PROTIA™ 
Allergy-Q 64 Atopy®, 0.15 kUA/L; ImmunoCAP®, 0.10 kUA/L). However, in a clinical setting, 
sIgE levels below 0.35 kUA/L is not considered to be meaningful. Therefore, these differences 
in the detection limits have little clinical significance. Third, PROTIA™ Allergy-Q 64 Atopy® 
does not detect other important major allergenic components, such as components of 
peanut, hazelnut, wheat, soy and fruits. Therefore, there is a need for further improvement 
to increase the numbers of detectable allergenic components.44 Fourth, diagnosis of enrolled 
patients was not confirmed by provocation test. Therefore, sensitivity, specificity, PPV and 
NPV could not be calculated. However, comparison with ImmunoCAP®, the gold standard for 
quantitative sIgE measurement can provide sufficient clinical meaning. Therefore, despite 
the limitations, the results of this study are still valid.
In conclusion, this study showed that PROTIA™ Allergy-Q 64 Atopy® shows high agreement 
with the ImmunoCAP® assay in detecting molecular allergen components. PROTIA™ 
Allergy-Q 64 Atopy®, a multiplex assay for detecting sIgE based on molecular allergens, may 
be a reliable and cost-effective alternative to component resolved diagnosis of allergic patients.
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